Based on our data, a combination of the backbone markers CD34, CD117, HLADR and CD45 supplemented with CD13, CD42a.CD61, CD36 and CD42b may allow for flowcytometric confirmation of AMKL diagnosis in patients highly suspected for AMKL based on morphological and/or clinical criteria. The gene discussed is GP9; the disease is acute megakaryoblastic leukemia.